Biocryst Pharmaceuticals
BioCryst Pharmaceuticals Inc is a commercial-stage biopharmaceutical enterprise headquartered in Durham, North Carolina. The company designs, develops, and commercializes novel small-molecule oral therapeutics targeted at rare and serious diseases driven by immune system dysfunction. Its primary commercial product is Orladeyo, an oral preventative treatment for hereditary angioedema. Principal revenue is derived through direct commercial sales of its approved pharmaceutical products alongside research collaboration grants. The enterprise serves clinical physicians and patients globally. BioCryst Pharmaceuticals Inc is publicly traded on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Biocryst Pharmaceuticals.
- Legal name
- BIOCRYST PHARMACEUTICALS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Biocryst Pharmaceuticals
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.19 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)